Cargando…

P1483: LONG-TERM IMPACT OF OLIPUDASE ALFA ENZYME REPLACEMENT THERAPY ON SPLEEN VOLUME AND HEMATOLOGIC MANIFESTATIONS IN CHILDREN AND ADULTS WITH CHRONIC ACID SPHINGOMYELINASE DEFICIENCY

Detalles Bibliográficos
Autores principales:	Villarrubia, Jesus, Ganesh, Jaya, Giugliani, Roberto, Guffon, Nathalie, Mengel, Eugen, Scarpa, Maurizio, Wasserstein, Melissa, Armstrong, Nicole, Maja, Gasparic, Kim, Yong, Wong, Holly, Yarramaneni, Abhimanyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430208/ http://dx.doi.org/10.1097/01.HS9.0000972816.18031.f6

Ejemplares similares

Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results
por: Diaz, George A., et al.
Publicado: (2022)

PB2314: OLIPUDASE ALFA FOR ADULTS WITH ACID SPHINGOMYELINASE DEFICIENCY: IMPROVEMENTS IN CROSSOVER PLACEBO PATIENTS AND FURTHER IMPROVEMENTS IN ORIGINAL OLIPUDASE ALFA PATIENTS AFTER 2 YEARS IN ASCEND TRIAL
por: Villarrubia, J., et al.
Publicado: (2022)

Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial
por: Wasserstein, Melissa P., et al.
Publicado: (2023)

Correction : Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results
por: Diaz, George A., et al.
Publicado: (2023)

Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults
por: Lachmann, Robin H., et al.
Publicado: (2023)

One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency
por: Diaz, George A., et al.
Publicado: (2021)

One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency
por: Diaz, George A., et al.
Publicado: (2022)

Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase Deficiency
por: Thurberg, Beth L., et al.
Publicado: (2016)

Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months
por: Wasserstein, Melissa P., et al.
Publicado: (2018)

Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use
por: Syed, Yahiya Y.
Publicado: (2023)

Correction to: Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use
por: Syed, Yahiya Y.
Publicado: (2023)

Quantitative Systems Pharmacology Modeling of Acid Sphingomyelinase Deficiency and the Enzyme Replacement Therapy Olipudase Alfa Is an Innovative Tool for Linking Pathophysiology and Pharmacology
por: Kaddi, Chanchala D., et al.
Publicado: (2018)

Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)
por: Wasserstein, Melissa, et al.
Publicado: (2018)

Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency
por: McGovern, Margaret M., et al.
Publicado: (2017)

Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation
por: McGovern, Margaret M., et al.
Publicado: (2021)

Hieronymus Fracastorius 1483—1553
por: Banerjee, A. K.
Publicado: (1988)

Changes in PCSK 9 and apolipoprotein B100 in Niemann–Pick disease after enzyme replacement therapy with olipudase alfa
por: Garside, Bethanie, et al.
Publicado: (2021)

Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa
por: Hughes, D., et al.
Publicado: (2017)

Royauté, Renaissance et Réforme, 1483-1559 /
por: Garrisson, Janine
Publicado: (1991)

Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann–Pick disease types A, B and A/B)
por: Geberhiwot, Tarekegn, et al.
Publicado: (2023)

Acid sphingomyelinase deficiency: The clinical spectrum of 2 patients who carry the Q294K mutation and diagnostic challenges
por: Blümlein, Ulrike, et al.
Publicado: (2022)

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study
por: Hendriksz, Christian J., et al.
Publicado: (2014)

Plasma lyso-sphingomyelin levels are positively associated with clinical severity in acid sphingomyelinase deficiency
por: Breilyn, Margo Sheck, et al.
Publicado: (2021)

Acid Sphingomyelinase Deficiency: Sharing Experience of Disease Monitoring and Severity in France
por: Mauhin, Wladimir, et al.
Publicado: (2022)

The R148.3 Gene Modulates Caenorhabditis elegans Lifespan and Fat Metabolism
por: Roy-Bellavance, Catherine, et al.
Publicado: (2017)

1483. Pleural Empyema Caused by Stenotrophomonas maltophilia in a National Cohort of Hospitalized Veterans
por: Masroujeh, Ramy, et al.
Publicado: (2018)

Early Depiction of a Parotid Tumour in the “School of Athens” (1509–1511) by Raphael (1483–1520)
por: Ashrafian, Hutan
Publicado: (2017)

1483 High Rate of Antibiotic Prescriptions for Outpatients with Influenza-Like Illness in Southern Sri Lanka
por: Tillekeratne, L. Gayani, et al.
Publicado: (2014)

Acid Sphingomyelinase Deficiency: A Clinical and Immunological Perspective
por: Pinto, Carolina, et al.
Publicado: (2021)

Su1483: COVID-19 VACCINES ARE HIGHLY EFFECTIVE IN PATIENTS WITH IBD: OUTCOMES FROM THE SCOUT IBD COHORT
por: Hong, Simon J., et al.
Publicado: (2022)

Report from LHC MDs 1391 and 1483: Tests of new methods for study of nonlinear errors in the LHC experimental insertions
por: Maclean, Ewen Hamish, et al.
Publicado: (2017)

Sphingomyelinases and Liver Diseases
por: Insausti-Urkia, Naroa, et al.
Publicado: (2020)

A pathogenic PHEX variant (c.1483-1G>C) in a Korean patient with X-linked hypophosphatemic rickets
por: Jeong, In Hwa, et al.
Publicado: (2021)

Neutral sphingomyelinase-2, acid sphingomyelinase, and ceramide levels in COPD patients compared to controls
por: Lea, Simon R, et al.
Publicado: (2016)

PB2361: PREDIGA, EDUCATIONAL AND DIAGNOSIS PROJECT IN ACID SPHINGOMYELINASE DEFICIENCY DISEASE (ASMD) AND GAUCHER DISEASE (GD): RESULTS TO THE OBJECTIVE ACHIEVED OF 200 PATIENTS ANALYZED.
por: Villarrubia, J., et al.
Publicado: (2022)

Acid sphingomyelinase deals the seal
por: Short, Ben
Publicado: (2010)

Phenotype Screening of an Azole-bisindole Chemical Library Identifies URB1483 as a New Antileishmanial Agent Devoid of Toxicity on Human Cells
por: Diotallevi, Aurora, et al.
Publicado: (2021)

A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease
por: Byrne, Barry J., et al.
Publicado: (2017)

Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
por: Dimachkie, Mazen M., et al.
Publicado: (2022)

Quantification of lysosphingomyelin and lysosphingomyelin-509 for the screening of acid sphingomyelinase deficiency
por: Kubaski, Francyne, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7htkav2pu3pr54kfao87o4p9fs